Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital-Reference-Cited by-同舟云学术

Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital

Published:2021-05-01 Issue:5 Volume:37 Page:350-356
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Borghetti Alberto¹,Bellino Stefania²,Lombardi Francesca³,Whalen Matteo³,Belmonti Simone³,Moschese Davide³,Ciccullo Arturo³,Tamburrini Enrica¹³,Baldin Gianmaria¹⁴,Dusina Alex³,Visconti Elena¹,Emiliozzi Arianna³,Lamonica Silvia¹,Pezzotti Patrizio²,Di Giambenedetto Simona¹³

Affiliation:

1. Fondazione Policlinico Universitario A, Gemelli IRCCS, Infectious Diseases, Rome, Italy.

2. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

3. Department of Safety and Bioethics, Section of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy.

4. Mater Olbia Hospital, Olbia, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0087

Reference27 articles.

1. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

2. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

3. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial